Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | FGR | P09769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19299601 | 0.95 | CES1 (0.49) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL11040014 | 0.78 | DNMT1 (0.50) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL11043679 | 0.78 | CYP1A1 (0.51) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL3967192 | 0.76 | ALDH1A1 (0.40) | CES1DNMT1MEN1KMT2AALDH1A1 | |
| SCHEMBL6905740 | 0.75 | MEN1 (0.76) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL3852137 | 0.74 | CDK4 (0.44) | CES1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11043607 | 0.74 | MAPT (0.62) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL10304672 | 0.74 | ALDH1A1 (0.41) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL1235463 | 0.73 | CES1 (0.49) | CES1DNMT1MEN1KMT2AMAPT | |
| SCHEMBL5850565 | 0.73 | MEN1 (0.58) | CES1DNMT1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8986852-B2 | Benzanthracene derivatives for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8986852-B2 | Benzanthracene derivatives for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2148909-B1 | BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20100187505-A1 | BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100187505-A1 | BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2008145239-A2 | BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100187505-A1 | BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES | KCNT1, KCNC1, TMEM109 | CES1 3672/4885DNMT1 1518/4885MEN1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.